Skip to main content

Table 2 Successfully validated dysregulated circRNAs in prostate cancer

From: The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer

  Cohort 1 Cohort 2
Upregulated in PC vs. AN Adj. P value FC AUC Adj. P value FC AUC
circABCC4 0.0004 1.62 0.71 < 0.0001 2.31 0.78
circZNF577 0.01 1.33 0.64 0.04 1.56 0.64
Downregulated in PCvs. AN Adj.value FC AUC Adj.value FC AUC
circFAT3 < 0.0001 − 3.14 0.82 < 0.0001 − 3.79 0.86
circITGA7 < 0.0001 − 2.31 0.75 < 0.0001 − 2.96 0.81
circATRNL1 < 0.0001 − 2.25 0.78 < 0.0001 − 5.54 0.85
circSLC45A4 < 0.0001 − 2.17 0.82 < 0.0001 − 1.96 0.85
circRNASEH2B < 0.0001 − 2.08 0.81 < 0.0001 − 2.00 0.81
circSEMA3C < 0.0001 − 2.07 0.80 < 0.0001 − 2.25 0.82
circSLC8A1 < 0.0001 − 2.04 0.76 < 0.0001 − 2.12 0.87
circARHGAP10 < 0.0001 − 2.01 0.79 < 0.0001 − 1.92 0.83
Downregulated in MPCvs. LPC value FC AUC value FC AUC
circMKLN1 0.0004 − 2.03 0.77 0.028 − 1.36 0.64
circN4BP2L2 0.03 − 1.77 0.67 < 0.0001 − 1.53 0.76
circZNF532 0.01 − 1.76 0.69 0.0002 − 1.78 0.74
circCDYL2 0.04 − 1.60 0.66 < 0.0001 − 2.19 0.76
circARHGAP10 0.001 − 2.13 0.76 0.001 − 1.74 0.71
  1. Results for the top dysregulated candidates in PC vs. AN and in MPC vs. LPC, respectively. For upregulated circRNAs in PC, all candidates significant in cohort 1 are shown. For downregulated circRNAs in PC, candidates with fold change > − 2 in cohort 1 are shown. For dysregulated circRNAs in LPC vs. MPC, candidates significant (uncorrected P < 0.05) in both cohorts 1 and 2 are shown (all downregulated)